BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Research Pipeline · 01 Jun 2026
Semax: The Russian-Approved Neuropeptide Now at the Centre of the FDA's July 2026 Compounding Review
Semax, a synthetic ACTH-derived heptapeptide approved in Russia for stroke recovery and cognitive impairment, was removed from the FDA's Category 2 restricted compounding list in April 2026 and is now scheduled for formal PCAC review on 24 July 2026. For UK research-procurement teams, its regulatory trajectory — and the evidentiary questions the advisory panel must resolve — make it one of the more consequential peptides to monitor this summer.
Read briefing →
Regulatory & Policy
The PCAC July 2026 Hearing: What the Four Day-One Peptides — BPC-157, TB-500, KPV, and MOTS-c — Need to Prove Before the Review
On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee will evaluate BPC-157, TB-500, KPV, and MOTS-c for potential inclusion on the Section 503A Bulk Drug Substances List. With the oral-testimony registration deadline on 30 June and the cut-off for comments reaching the committee on 9 July, procurement teams have weeks — not months — to understand what is at stake.
01 Jun 2026
Pharma & GLP-1
Retatrutide's TRIUMPH-1 Phase 3 Data: 28.3% Weight Loss, a Pending NDA, and What It Means for Research Labs
Eli Lilly's triple agonist retatrutide delivered up to 28.3% average body-weight reduction at 80 weeks in the Phase 3 TRIUMPH-1 trial, with a 30.3% result at 104 weeks in a high-BMI sub-group. The data, released 21 May 2026, sets a new efficacy benchmark in the GLP-1 class — and is already intensifying procurement interest in research-grade retatrutide, despite the compound remaining strictly investigational and not compoundable under any current legal pathway.
30 May 2026
Industry & Community
The Macrocyclic Peptide Investment Wave: What Three Major 2026 Deals Signal for the Research Landscape
A cluster of substantial deals in early 2026 — including Novartis's $100 million upfront commitment to Unnatural Products, Syneron Bio's $150 million Series B, and AstraZeneca's ongoing $3.4 billion biobucks arrangement — marks macrocyclic peptides as the modality attracting the most concentrated institutional attention in the peptide space. For research-procurement teams, understanding what distinguishes macrocycles from conventional linear peptides, and why big pharma is now paying platform…
30 May 2026
Research Pipeline
Oral Peptide Therapeutics Reach an Inflection Point: ICOTYDE's Approval, Pinnacle's $89M Raise, and What the Delivery Revolution Means for Research Labs
The FDA approval of icotrokinra (ICOTYDE) as the first targeted oral peptide to block the IL-23 receptor marks a structural shift in peptide drug delivery. Combined with a wave of investment in oral-peptide platforms and an upcoming PCAC advisory meeting, the field is entering a period of rapid technical and regulatory change that procurement teams need to understand.
29 May 2026
Regulatory & Policy
FDA Moves to Close 503B Compounding Pathway for GLP-1 Peptides — What the April Proposal Means Before the June Comment Deadline
On 30 April 2026, the FDA proposed formally excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulk Drug Substances List, citing no clinical need for outsourcing facilities to compound these agents. The public comment window closes 29 June 2026 — and the implications extend well beyond US compounders to research procurement teams tracking GLP-1 supply integrity globally.
29 May 2026
Research Pipeline
What the 2026 Orthopaedic Literature Says About Research Peptides — and Why It Matters for Procurement
A peer-reviewed review in JAAOS: Global Research & Reviews has systematically mapped the mechanism and evidence base for BPC-157, TB-500, GHK-Cu, Ipamorelin, CJC-1295 and related compounds in musculoskeletal medicine. The findings underscore a persistent gap between preclinical promise and human trial data — a distinction that carries direct implications for research-procurement professionals sourcing these compounds and for how suppliers should frame their documentation.
28 May 2026
Research Pipeline
Thymosin Alpha-1: The Peptide With the Strongest Clinical Evidence Base — and a Complicated Regulatory Story
Thymosin alpha-1 (Tα1) is approved as a prescription drug in more than 35 countries and has been evaluated in over 80 clinical trials. Yet its US compounding status remains unsettled, and a large 2025 phase 3 trial returned a negative primary endpoint in sepsis. For UK research-procurement professionals, it is arguably the most evidence-rich peptide on the market — and among the most instructive in understanding how clinical nuance shapes regulatory outcome.
24 May 2026
Pharma & GLP-1
CHMP Backs Both High-Dose Wegovy HD and Oral Semaglutide for EU Approval — What the Twin Opinions Mean for the Research Landscape
On 22 May 2026, the EMA's Committee for Medicinal Products for Human Use issued positive opinions recommending EU marketing authorisation for both Wegovy HD 7.2 mg in a single-dose pen and the oral Wegovy pill (semaglutide 25 mg). The twin rulings advance semaglutide into new dosing and delivery territory across Europe — with distinct implications for UK regulatory timelines, research procurement, and the purity concerns that continue to surround the grey-market semaglutide supply chain.
24 May 2026
Research Pipeline
GHK-Cu: The Copper Tripeptide Facing Its Second Regulatory Wave — What Research Labs Need to Know
GHK-Cu (copper tripeptide-1) has one of the stronger mechanistic evidence bases among research peptides, spanning wound healing, collagen remodelling, and genomic modulation of over a thousand genes. Following the FDA's April 2026 Federal Register notice, it now sits in the second wave of PCAC review, scheduled before February 2027. This briefing covers its biochemistry, the state of the clinical evidence, and what the split regulatory picture means for UK procurement teams.
24 May 2026
Pharma & GLP-1
EASO's 2026 Living Algorithm Separates Tirzepatide and Semaglutide by Indication — With MASH Data Sharpening the Divide
The European Association for the Study of Obesity has published its first update to its GLP-1 pharmacotherapy framework, drawing a clearer evidence-based distinction between tirzepatide and semaglutide. Tirzepatide now sits above semaglutide for total body weight loss, while semaglutide is the only agent currently supported for liver fibrosis improvement — a split with direct implications for research strategy as Novo Nordisk advances its MASH programme into EASL 2026.
21 May 2026
Reputational Risks
GLP-1 Popularity Is Fuelling Unverified Peptide Promotion Online — and Raising Purity Concerns for Research Procurement
The clinical success of injectable GLP-1 drugs has triggered a surge of social media promotion for a much broader range of unverified peptides, with physicians warning that many products contain minimal active ingredient or outright contaminants. For research-procurement professionals, the same market dynamics create real supply-chain risks that standard vendor screening must address.
19 May 2026